Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases

被引:12
作者
Kibiki, Gibson S.
van der Ven, Andre J. A. M.
Geurts-Moespot, Anneke
Shao, John
Calandra, Thierry
Sweep, Fred C. G. J.
Dolmans, Wil M. V.
机构
[1] Tumaini Univ, KCMC, Dept Internal Med, Endoscopy Unit, Moshi, Tanzania
[2] Tumaini Univ, KCMC, Dept Med Microbiol, Moshi, Tanzania
[3] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Div Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands
[5] CHU Vaudois, Dept Internal Med, Infect Dis Serv, CH-1011 Lausanne, Switzerland
关键词
MIF; BAL; serum; HIV; pulmonary TB; CD4; count; mortality;
D O I
10.1016/j.clim.2006.12.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Macrophage migration inhibitory factor (MIF) activates macrophages, promotes delayed-type hypersensitivity reaction, and regulates Th1/Th2 balance in inflammatory response. Serum MIF concentration is high in patients with pulmonary tuberculosis (PTB). Higher MIF levels are associated with high mortality. No study has addressed MIF levels and its role in PTB/HIV-co infection. We determined serum and BAL MIF levels in Tanzanian HIV-infected patients with and without PTB, and correlated the levels with 1-month outcome. We compared with serum MIF levels of HIV seronegative patients with PTB and of healthy controls. All HIV-infected patients irrespective of PTB infection had significantly higher serum MIF levels than HIV-seronegative patients with PTB, and than healthy controls. In HIV seropositive patients tow serum MIF levels were associated with high 1-month mortality. In conclusion, HIV infection was associated with elevated serum MIF levels regardless of PTB. Low serum MIF levels were associated with high mortality. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 28 条
[1]   Tuberculosis and HIV disease: Two decades of a dual epidemic [J].
Aliyu, MH ;
Salihu, HM .
WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (19-20) :685-697
[2]   HERPES-LIKE SEQUENCES IN HIV-INFECTED AND UNINFECTED KAPOSIS-SARCOMA PATIENTS [J].
AMBROZIAK, JA ;
BLACKBOURN, DJ ;
HERNDIER, BG ;
GLOGAU, RG ;
GULLETT, JH ;
MCDONALD, AR ;
LENNETTE, ET ;
LEVY, JA .
SCIENCE, 1995, 268 (5210) :582-583
[3]   An essential regulatory role for macrophage migration inhibitory factor in T-cell activation [J].
Bacher, M ;
Metz, CN ;
Calandra, T ;
Mayer, K ;
Chesney, J ;
Lohoff, M ;
Gemsa, D ;
Donnelly, T ;
Bucala, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7849-7854
[4]   Macrophage migration inhibitory factor [J].
Baugh, JA ;
Bucala, R .
CRITICAL CARE MEDICINE, 2002, 30 (01) :S27-S35
[5]   Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness [J].
Beishuizen, A ;
Thijs, LG ;
Haanen, C ;
Vermes, I .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06) :2811-2816
[6]   MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA [J].
BERNHAGEN, J ;
CALANDRA, T ;
MITCHELL, RA ;
MARTIN, SB ;
TRACEY, KJ ;
VOELTER, W ;
MANOGUE, KR ;
CERAMI, A ;
BUCALA, R .
NATURE, 1993, 365 (6448) :756-759
[7]   An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction [J].
Bernhagen, J ;
Bacher, M ;
Calandra, T ;
Metz, CN ;
Doty, SB ;
Donnelly, T ;
Bucala, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (01) :277-282
[8]   Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis [J].
Bozza, M ;
Satoskar, AR ;
Lin, GS ;
Lu, B ;
Humbles, AA ;
Gerard, C ;
David, JR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :341-346
[9]  
BUTCHER HC, 1999, ACIDS, V13, P501
[10]   Macrophage migration inhibitory factor (MIF): A glucocorticoid counter-regulator within the immune system [J].
Calandra, T ;
Bucala, R .
CRITICAL REVIEWS IN IMMUNOLOGY, 1997, 17 (01) :77-88